Fiche centre
Toronto Memory Program
Toronto — Canada
Essais liés7clinical trials
VilleTorontolocalisation
PaysCanadalocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT04437511
Essais cliniques associés
7| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| RO7126209 | Alzheimer | Phase 1/2 | NCT04639050 | Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease | ACTIVE_NOT_RECRUITING |
| Prasinezumab | Parkinson | Phase 2 | NCT04777331 | PADOVA — A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease | ACTIVE_NOT_RECRUITING |
| Trontinemab | Alzheimer | Phase 3 | NCT07717411 | PrevenTRON — A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease | RECRUITING |
| Donanemab | Alzheimer | Phase 3 | NCT04437511 | A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) | ACTIVE_NOT_RECRUITING |
| Trontinemab | Alzheimer | Phase 3 | NCT07169578 | TRONTIER 1 — A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease | RECRUITING |
| Rimegepant 75mg daily dosing | Migraine | Phase 4 | NCT05217927 | Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens | COMPLETED |
| A Post Authorization Registry Study of Participants Treated With LEQEMBI | Alzheimer | À vérifier | NCT07762092 | A Post Authorization Registry Study of Participants Treated With LEQEMBI | NOT_YET_RECRUITING |